CORAVAX (SARS-COV2-Rabies Vector) / Thomas Jefferson University, Bharat Biotech - LARVOL DELTA

Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity. (PubMed, NPJ Vaccines) - "We believe this rabies-vector strategy combats the problem of waning immunity of other COVID-19 vaccines. These results together support CORAVAX's potential during the ongoing COVID-19 pandemic."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • TLR4

A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. (PubMed, Viruses) - "We also observed high Rabies VNA titers. In summary, CORAVAX is a promising dual-antigen vaccine candidate for clinical evaluation against SARS-CoV-2 and Rabies virus."

Journal • Preclinical • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. (PubMed, PLoS Pathog) - "CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Bharat Biotech, Thomas Jefferson University pursue a promising vaccine candidate against Covid-19 (PRNewswire) - "Global Leader and vaccine innovator Bharat Biotech and Thomas Jefferson University of Philadelphia have signed an exclusive deal to develop a new vaccine candidate for COVID-19 invented at Jefferson....Under the license agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson's vaccine across the world excluding countries such as USA, Europe, Japan etc., where Jefferson continues to seek partners. With support from the Department of Biotechnology, Govt. of India, Bharat Biotech aims to get into human trials as soon as December 2020."

Licensing / partnership • New trial • Infectious Disease • Novel Coronavirus Disease